Cargando…

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review

Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the adult population. The course of CML is divided into three phases: the chronic phase, the acceleration phase, and the blast phase. Pathophysiology of CML revolves around Philadelphia chromosome that constitutively act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinaldi, Ikhwan, Winston, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084831/ https://www.ncbi.nlm.nih.gov/pubmed/37051025 http://dx.doi.org/10.2147/JBM.S382090

Ejemplares similares

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
por: Dulucq, Stéphanie, et al.
Publicado: (2016)

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
por: Hughes, Amy, et al.
Publicado: (2017)

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
por: Kwaśnik, Paulina, et al.
Publicado: (2021)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy
por: Hadisantoso, Dwi Wahyunianto, et al.
Publicado: (2022)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
por: Caocci, Giovanni, et al.
Publicado: (2016)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
por: Lou, Jin, et al.
Publicado: (2018)

Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
por: Sharf, Giora, et al.
Publicado: (2020)

Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
por: Saifullah, Hilbeen Hisham, et al.
Publicado: (2021)

Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia
por: Fujioka, Yuki, et al.
Publicado: (2021)

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
por: Pavlovsky, Carolina, et al.
Publicado: (2021)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
por: Yoshida, Chikashi, et al.
Publicado: (2023)

Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients – A Dual-Center Retrospective Cohort Study
por: Rinaldi, Ikhwan, et al.
Publicado: (2021)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
por: Sutandyo, Noorwati, et al.
Publicado: (2022)

Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon
por: Elias, Fadia, et al.
Publicado: (2019)

Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
por: Mu, Hui, et al.
Publicado: (2021)

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
por: Yamazaki, Kiyotaka, et al.
Publicado: (2020)

Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
por: Vigón, Lorena, et al.
Publicado: (2020)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Ito, Kyoko, et al.
Publicado: (2021)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
por: Hochhaus, A, et al.
Publicado: (2017)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission
por: Stuckey, Ruth, et al.
Publicado: (2022)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
por: Radich, Jerald P., et al.
Publicado: (2021)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
por: Capodanno, Isabella, et al.
Publicado: (2021)

Planned Pregnancy in a Chronic Myeloid Leukemia Patient in Molecular Remission
por: Pavlovsky, Carolina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p3pdfik3kntigi0k3og4gulbjg